Highlights for the Q3 FY22 Quarter Include: • Technology transfer for manufacturing Combo SARSCoV-2 Influenza A/B Ag Rapid Diagnostic Test (RDT) with Operon has commenced. • Australian clinical trial progresses as planned. • Contracted Clinical Research Organisation (CRO) in Spain to conduct prospective clinical trials for COVID19 RAT - to support TGA and EU Common List registrations • Distributor stocking and customer orders for EuGeni Readers and Covid-19 RATs in Europe. • Continued technical progress with collaborators with results demonstrating that AnteoX binder formulation improved the test battery's cycle life by up to 100% at 70% capacity retention. • AnteoX increased anode tensile strength by up to 56%, helping to manage the volume expansion of silicon-containing anodes, thereby improving battery electrochemical performance and longevity
yes, ..... and also the battery milestones in this ANN:ASX is what Merc and Ford have been touting in their latest EV promotions. as already discussed significant news is due.
ADO Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
